nach oben

Geriatrie-Report

Erschienen in:

15.08.2019 | Veränderungen von Knochendichte und Knochenstruktur | Zertifizierte Fortbildung

Wenn die Knochen brüchig werden

Osteoporose: Oberstes Ziel ist die Vermeidung von Frakturen

verfasst von: Dr. Franca Genest, MA, Dr. Lothar Seefried

Erschienen in: Geriatrie-Report | Ausgabe 3/2019

Einloggen, um Zugang zu erhalten

Zusammenfassung

Vitamin-D-Mangel, Medikamente, Multimorbidität — im Alter häufen sich die Risikofaktoren für osteoporotische Knochenbrüche. Insbesondere für ältere Menschen sind Frakturen ein einschneidendes Erlebnis, dass nicht selten zu Immobilität oder Pflegebedürftigkeit führt. Um ein erhöhtes Risiko frühzeitig zu erkennen und adäquat reagieren zu können, sollte der Hausarzt die richtigen Fragen stellen und die Warnzeichen für drohende Knochenbrüche kennen.

Jakob F, Seefried L, Schwab M. [Age and osteoporosis. Effects of aging on osteoporosis, the diagnostics and therapy]. Der Internist. 2014;55(7):755–61.PubMedCrossRef

Van Der Klift M, Pols HA, Geleijnse JM, Van Der Kuip DA, Hofman A, De Laet CE. Bone mineral density and mortality in elderly men and women: the Rotterdam Study. Bone. 2002;30(4):643–8.PubMedCrossRef

Hadji P, Klein S, Gothe H, Haussler B, Kless T, Schmidt T, et al. The epidemiology of osteoporosis—Bone Evaluation Study (BEST): an analysis of routine health insurance data. Deutsches Arzteblatt international. 2013;110(4):52–7PubMedPubMedCentral

Jakob F, Seefried L, Ebert R. [Pathophysiology of bone metabolism]. Der Internist. 2008;49(10):1159–60, 62, 64 passim.PubMedCrossRef

Bar-Shavit Z. The osteoclast: a multinucleated, hematopoietic-origin, bone-resorbing osteoimmune cell. Journal of cellular biochemistry. 2007;102(5):1130–9.PubMedCrossRef

Novack DV, Teitelbaum SL. The osteoclast: friend or foe? Annu Rev Pathol. 2008;3:457–84.CrossRef

DVO. Prophylaxe, Diagnostik und Therapie der OSTEOPOROSE bei postmenopausalen Frauen und bei Männern 2017 [cited 2019 2 May]. Available from: https://www.dv-osteologie.org/uploads/Leitlinie%202017/Finale%20Version%20Leitlinie%20Osteoporose%202017_end.pdf.

Johnell O, Kanis JA, Oden A, Sernbo I, Redlund-Johnell I, Petterson C, et al. Fracture risk following an osteoporotic fracture. Osteoporos Int. 2004;15(3):175–9.PubMedCrossRef

Kanis JA, Johnell O, De Laet C, Johansson H, Oden A, Delmas P, et al. A meta-analysis of previous fracture and subsequent fracture risk. Bone. 2004;35(2):375–82.PubMedCrossRef

10.

Lunt M, O’Neill TW, Felsenberg D, Reeve J, Kanis JA, Cooper C, et al. Characteristics of a prevalent vertebral deformity predict subsequent vertebral fracture: results from the European Prospective Osteoporosis Study (EPOS). Bone. 2003;33(4):505–13.PubMedCrossRef

11.

Eklund F, Nordstrom A, Bjornstig U, Nordstrom P. Bone mass, size and previous fractures as predictors of prospective fractures in an osteoporotic referral population. Bone. 2009;45(4):808–13.PubMedCrossRef

12.

Franca Genest LS. Süße Knochen brechen leichter. Der Allgemeinarzt 2018;40 (17) Seite 34–8.

13.

Napoli N, Chandran M, Pierroz DD, Abrahamsen B, Schwartz AV, Ferrari SL, et al. Mechanisms of diabetes mellitus-induced bone fragility. Nature reviews Endocrinology. 2017;13(4):208–19.PubMedCrossRef

14.

Bonds DE, Larson JC, Schwartz AV, Strotmeyer ES, Robbins J, Rodriguez BL, et al. Risk of fracture in women with type 2 diabetes: the Women’s Health Initiative Observational Study. J Clin Endocrinol Metab. 2006;91(9):3404–10.PubMedCrossRef

15.

Ma L, Oei L, Jiang L, Estrada K, Chen H, Wang Z, et al. Association between bone mineral density and type 2 diabetes mellitus: a meta-analysis of observational studies. Eur J Epidemiol. 2012;27(5):319–32.PubMedPubMedCentralCrossRef

16.

Farr JN, Zhang W, Kumar SK, Jacques RM, Ng AC, McCready LK, et al. Altered cortical microarchitecture in patients with monoclonal gammopathy of undetermined significance. Blood. 2014;123(5):647–9.PubMedPubMedCentralCrossRef

17.

Drake MT. unveiling skeletal fragility in patients diagnosed with MGUS: no longer a condition of undetermined significance? J Bone Miner Res. 2014;29(12):2529–33.PubMedPubMedCentralCrossRef

18.

Seppala LJ, van der Velde N, Masud T, Blain H, Petrovic M, van der Cammen TJ, et al. EuGMS Task and Finish group on Fall-Risk-Increasing Drugs (FRIDs): Position on Knowledge Dissemination, Management, and Future Research. Drugs Aging. 2019;36(4):299–307.PubMedPubMedCentralCrossRef

19.

Picca A, Calvani R, Manes-Gravina E, Spaziani L, Landi F, Bernabei R, et al. Bone-Muscle Crosstalk: Unraveling New Therapeutic Targets for Osteoporosis. Current pharmaceutical design. 2017;23(41):6256–63.PubMedCrossRef

20.

Wagner P, Chapurlat R, Ecochard R, Szulc P. Low Muscle Strength and Mass Is Associated With the Accelerated Decline of Bone Microarchitecture at the Distal Radius in Older Men: the Prospective STRAMBO Study. J Bone Miner Res. 2018;33(9):1630–40.PubMedCrossRef

21.

Jain RK, Vokes T. Dual-energy X-ray Absorptiometry. Journal of clinical densitometry: the official journal of the International Society for Clinical Densitometry. 2017;20(3):291–303.CrossRef

22.

Lewiecki EM. Bone densitometry and vertebral fracture assessment. Current osteoporosis reports. 2010;8(3):123–30.PubMedCrossRef

23.

Flicker L, Mead K, MacInnis RJ, Nowson C, Scherer S, Stein MS, et al. Serum vitamin D and falls in older women in residential care in Australia. J Am Geriatr Soc. 2003;51(11):1533–8.PubMedCrossRef

24.

Garnero P, Munoz F, Sornay-Rendu E, Delmas PD. Associations of vitamin D status with bone mineral density, bone turnover, bone loss and fracture risk in healthy postmenopausal women. The OFELY study. Bone. 2007;40(3):716–22.PubMedCrossRef

25.

Sambrook PN, Chen JS, March LM, Cameron ID, Cumming RG, Lord SR, et al. Serum parathyroid hormone is associated with increased mortality independent of 25-hydroxy vitamin d status, bone mass, and renal function in the frail and very old: a cohort study. J Clin Endocrinol Metab. 2004;89(11):5477–81.PubMedCrossRef

26.

Pfeifer M, Begerow B, Minne HW, Suppan K, Fahrleitner-Pammer A, Dobnig H. Effects of a long-term vitamin D and calcium supplementation on falls and parameters of muscle function in community-dwelling older individuals. Osteoporos Int. 2009;20(2):315–22.PubMedCrossRef

27.

Larsen ER, Mosekilde L, Foldspang A. Vitamin D and calcium supplementation prevents osteoporotic fractures in elderly community dwelling residents: a pragmatic population-based 3-year intervention study. J Bone Miner Res. 2004;19(3):370–8.PubMedCrossRef

28.

Saita Y, Ishijima M, Kaneko K. Atypical femoral fractures and bisphosphonate use: current evidence and clinical implications. Therapeutic advances in chronic disease. 2015;6(4):185–93.PubMedPubMedCentralCrossRef

29.

Shane E, Burr D, Ebeling PR, Abrahamsen B, Adler RA, Brown TD, et al. Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res. 2010;25(11):2267–94.PubMedCrossRef

30.

Shane E, Burr D, Abrahamsen B, Adler RA, Brown TD, Cheung AM, et al. Atypical subtrochanteric and diaphyseal femoral fractures: second report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res. 2014;29(1):1–23.PubMedCrossRef

31.

Bone HG, Wagman RB, Brandi ML, Brown JP, Chapurlat R, Cummings SR, et al. 10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension. Lancet Diabetes Endocrinol. 2017;5(7):513–23.PubMedCrossRef

32.

Watts NB, Brown JP, Papapoulos S, Lewiecki EM, Kendler DL, Dakin P, et al. Safety Observations With 3 Years of Denosumab Exposure: Comparison Between Subjects Who Received Denosumab During the Randomized FREEDOM Trial and Subjects Who Crossed Over to Denosumab During the FREEDOM Extension. J Bone Miner Res. 2017;32(7):1481–5.PubMedCrossRef

33.

Cummings SR, San Martin J, McClung MR, Siris ES, Eastell R, Reid IR, et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med. 2009;361(8):756–65.PubMedCrossRef

34.

Tsourdi E, Langdahl B, Cohen-Solal M, Aubry-Rozier B, Eriksen EF, Guanabens N, et al. Discontinuation of Denosumab therapy for osteoporosis: A systematic review and position statement by ECTS. Bone. 2017;105:11–7.PubMedCrossRef

35.

Leder BZ. Optimizing Sequential and Combined Anabolic and Antiresorptive Osteoporosis Therapy. JBMR Plus. 2018;2(2):62–8.PubMedPubMedCentralCrossRef

36.

Leder BZ, Tsai JN, Jiang LA, Lee H. Importance of prompt antiresorptive therapy in postmenopausal women discontinuing teriparatide or denosumab: The Denosumab and Teriparatide Follow-up study (DATA-Follow-up). Bone. 2017;98:54–8.PubMedCrossRef

37.

Lewiecki EM, Dinavahi RV, Lazaretti-Castro M, Ebeling PR, Adachi JD, Miyauchi A, et al. One Year of Romosozumab Followed by Two Years of Denosumab Maintains Fracture Risk Reductions: Results of the FRAME Extension Study. J Bone Miner Res. 2019;34(3):419–28.PubMedCrossRef

38.

McClung MR. Romosozumab for the treatment of osteoporosis. Osteoporos Sarcopenia. 2018;4(1):11–5.PubMedPubMedCentralCrossRef

39.

Lewiecki EM, Blicharski T, Goemaere S, Lippuner K, Meisner PD, Miller PD, et al. A Phase III Randomized Placebo-Controlled Trial to Evaluate Efficacy and Safety of Romosozumab in Men With Osteoporosis. J Clin Endocrinol Metab. 2018;103(9):3183–93.PubMedCrossRef

40.

Cosman F, Crittenden DB, Adachi JD, Binkley N, Czerwinski E, Ferrari S, et al. Romosozumab Treatment in Postmenopausal Women with Osteoporosis. N Engl J Med. 2016;375(16):1532–43.PubMedCrossRef

Titel: Wenn die Knochen brüchig werden
Osteoporose: Oberstes Ziel ist die Vermeidung von Frakturen
verfasst von: Dr. Franca Genest, MA
Dr. Lothar Seefried
Publikationsdatum: 15.08.2019
Verlag: Springer Medizin
Schlagwörter: Veränderungen von Knochendichte und Knochenstruktur
Osteoporose
Allgemeine Diagnostik
Bisphosphonate
Osteoporose
Denosumab
Denosumab
Geriatrie und Gerontologie
Geriatrie in der Hausarztpraxis
Erschienen in: Geriatrie-Report / Ausgabe 3/2019
Print ISSN: 1862-5363
Elektronische ISSN: 2520-8950
DOI: https://doi.org/10.1007/s42090-019-0179-6

Fitmachen fürs EKG-Befunden - Der Video-Kurs jetzt mit 10 CME-Punkten

Springer Medizin

Zusammenfassung

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2019

SGLT-2-Hemmer hilft Diabetikern mit Herzinsuffizienz

99 und multimorbide: Würden Sie hier noch operieren?

Rehabilitation nach Hüftfraktur: Entscheidend sind die ersten sechs Monate

Gesucht: Junge Ärzte für alte Patienten

Tipps für die Tumorschmerz-Therapie

Vom Kindheitstrauma eingeholt